过去一年,医疗行业的人才架构经历了显著转型,从传统的“金字塔”型,逐步演变为以中高端人才为主体的“钻石型”结构。这一变化不仅反映了行业对专业能力与综合素质要求的提升,也促使企业在招聘策略上,从过去追求速度与规模的“唯快不破”,转向更加注重质量与匹配度的“稳中求进”。与此同时,职业发展的可持续性与企业文化的契合度,日益成为优秀人才选择平台的重要考量,成为企业在人才争夺战中脱颖而出的关键因素。
过去一年,医疗行业的人才架构经历了显著转型,从传统的“金字塔”型,逐步演变为以中高端人才为主体的“钻石型”结构。这一变化不仅反映了行业对专业能力与综合素质要求的提升,也促使企业在招聘策略上,从过去追求速度与规模的“唯快不破”,转向更加注重质量与匹配度的“稳中求进”。与此同时,职业发展的可持续性与企业文化的契合度,日益成为优秀人才选择平台的重要考量,成为企业在人才争夺战中脱颖而出的关键因素。
PeopleSearch brings the 《2024 Pharmaceutical Industry Market Talent Trends In China》by summarizing the past changes and future direction of the pharmaceutical industry from three dimensions: industry talent market, organizational development, and candidate thinking. Now, PeopleSearch Pharmaceuticals team is relaunching the […]
受到當前多變的經營環境與消費者保守心態影響,多數企業成長明顯放緩,並停止擴張策略。隨著AI 智能轉型風潮,技術的進步將顛覆傳統電腦產業,同時促進科技服務業的成長。PeopleSearch 觀察到企業正面臨留才挑戰,強調提升薪資與學習機會是留才的關鍵策略。
Watch our 2023 AGM below. It covers our annual report, a reflection of our achievements in the past year, and a presentation of our financial outlook moving forward.
职场机会平等是企业长期可持续发展的核心竞争力之一。HRnetGroup向1527名受访者发起调研,并将调查结果进行整理,发布这份《2023职场机会平等现状调研报告》。
HRnetGroup希望能够通过与大家共同探讨组织面临的职场机会平等挑战及优秀企业案例,帮助企业做出更具多元化、平等和包容性的决策。
良好的领导力是具有感染力的。在当今竞争激烈的环境中,领导者要不断发展自身能力,才能有效地提高员工的敬业度,帮助企业更好地吸引与保留顶尖人才。
This year marked the 30th Anniversary of our Group and to commemorated the special occasion, we organised a Walkathon and Fundraising event on 3 September 2022. Themed, Walk With Us, the objective of the event was to support and give […]
Our “Walk With Us” walkathon & fundraising event was held successfully in September across 11 cities! More than 600 people joined our walkathons which took place in Singapore, Kuala Lumpur, Hong Kong, Taipei, Tokyo, Shanghai, Beijing, Guangzhou, Seoul, Jakarta and […]
We’re pleased to announce our results for 1H 2022! HRnetGroup recorded strong increases in top lines with Revenue of S$314.2m, up 14.2% and Gross Profit S$91.9m, up 12.3%. GP margin sustained at 29.3% (1H 2021: 29.7%).
We’re pleased to announce our results for 1H 2022! HRnetGroup recorded strong increases in top lines with Revenue of S$314.2m, up 14.2% and Gross Profit S$91.9m, up 12.3%. GP margin sustained at 29.3% (1H 2021: 29.7%).